Log in to search using one of your social media accounts:

 

7 medtech stories we missed this week: Sept. 15, 2017
[Image from unsplash.com]From Acera Surgical and Telos Medical’s partnership to Xtant Medical’s 510(k) clearance, here are seven medtech stories we missed this week but thought were still worth a mention. 1. Acera Surgical partners with Telos Medical for Restrata wound matrix trial Telos Partners announced in a Sept. 14 press release that Acera Surgical has chosen Telos to lead its Restrata wound matrix study. The study will surgery the clinical outcomes of Restrata treatments for diabetic foot ulcers and test for effectiveness and safety. Restrata is a fully synthetic wound matrix that is FDA-cleared for ...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Business/Financial News Clinical Trials Dental Diagnostics Food & Drug Administration (FDA) Regulatory/Compliance Surgical Acera Surgical Contego Medical Fresenius MedTech OBP Medical Pinnacle Sciences Plusoptix Telos Source Type: news

This smart mat can predict the onset of foot ulcers
[Image from Podimetrics/MIT News]A Massachusetts Institute of Technology hackathon participant developed a smart mat that helps detect early warning signs of foot ulcers. Jon Bloom, co-founder of startup company Podimetrics, developed a mat that can detect foot ulcers before they happen and reduce the number of amputations occurring. Bloom completed his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s and saw a lot of diabetic patients go through foot amputations because of infected foot ulcers. Read the whole story on our sister site, Medical Design & Outsourcing The post This smart ...
Source: Mass Device - September 12, 2017 Category: Medical Devices Authors: Chris Newmarker Tags: Diabetes Diagnostics Wound Care Massachusetts Institute of Technology Source Type: news

Type 2 diabetes complications - levels of amputations at ‘record high’
DIABETES can be a complex condition to manage - and if it is not managed successfully the condition can lead to foot ulcers and amputation. (Source: Daily Express - Health)
Source: Daily Express - Health - September 10, 2017 Category: Consumer Health News Source Type: news

Type 2 diabetes warning - how the weather could increase risk of THIS complication
TYPE 2 diabetes complications can include foot ulcers which can go unnoticed by people with the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - September 8, 2017 Category: Consumer Health News Source Type: news

Type 2 diabetes breakthrough - app could detect THIS dangerous complication
TYPE 2 diabetes can cause considerable complications if it is not managed effectively. One of the complications of the condition are foot ulcers. (Source: Daily Express - Health)
Source: Daily Express - Health - September 5, 2017 Category: Consumer Health News Source Type: news

MiMedx Reports MultiCenter randomized Controlled VLU Clinical Study Accepted for Publication in The International Wound Journal
Unparalleled Results of 60% healing at 12 Weeks and 71% Healing at 16 Weeks Expected to Expand VLU Insurance Coverage to an Additional $75 Million to $150 Million in annual Revenue Opportunity MARIETTA, Ga., Aug. 31, 2017 -- (Healthcare Sales & Marketin... Biopharmaceuticals, Regenerative Medicine, Wound Care MiMedx Group, EpiFix, Venous Leg Ulcer, Diabetic Foot Ulcer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 31, 2017 Category: Pharmaceuticals Source Type: news

Type 2 diabetes patients at greater risk of THIS potentially life-threatening condition
TYPE 2 diabetes sufferers can face a host of other complications and symptoms - foot ulcers and kidney problems. It is also linked to muscular issues but can even increase the risk of hypothyroidism. (Source: Daily Express - Health)
Source: Daily Express - Health - August 18, 2017 Category: Consumer Health News Source Type: news

Type 2 diabetes news: Foot ulcers could be prevented with THIS new test
FOOT ulcers are a major complication for millions of people with type 2 diabetes. Now experts believe they have found a system to reduce the number of foot amputations among patients with diabetes. (Source: Daily Express - Health)
Source: Daily Express - Health - August 17, 2017 Category: Consumer Health News Source Type: news

Foot ulcers - complication of type 2 diabetes could be prevented with THIS new test
FOOT ulcers are a major complication for millions of people with type 2 diabetes. Now experts believe they have found a system to reduce the number of foot amputations among patients with diabetes. (Source: Daily Express - Health)
Source: Daily Express - Health - August 17, 2017 Category: Consumer Health News Source Type: news

VM BioPharma begins dosing in Phase III trial of VM202 for NHU and PAD
Korean biopharmaceutical company ViroMed ’s US division VM BioPharma has begun dosing patients with VM202 in a Phase III clinical trial to treat non-healing diabetic foot ulcers (NHU) and associated peripheral artery disease (PAD). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news

VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers
First Pivotal Gene Therapy Trial to Target Underlying Peripheral Artery Disease in Non-Healing Diabetic Foot Ulcers ATLANTA, Aug. 3, 2017 -- (Healthcare Sales & Marketing Network) -- VM BioPharma, the United States division of ViroMed Co., Ltd. in Seou... Biopharmaceuticals, Wound Care VM BioPharma, VM202, diabetic foot ulcer, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 3, 2017 Category: Pharmaceuticals Source Type: news

New Startup Aims to Stamp out Diabetic Foot Ulcers
(Source: MDDI)
Source: MDDI - August 1, 2017 Category: Medical Devices Authors: MDDI Staff Tags: Medical Device Business Source Type: news

Enzymatic Debridement of Chronic Diabetic Foot Ulcers Enzymatic Debridement of Chronic Diabetic Foot Ulcers
What benefits might enzymatic debridement with clostridial collagenase ointment provide in the treatment of diabetic foot ulcers?Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Heartburn drugs linked to premature death
Conclusion This larger set of observational data finds that PPI drugs are associated with an increase in the risk of early death compared with either H2 blockers or no acid suppression drugs. This was the case for participants both with and without gastrointestinal problems. It also appears as though the longer the PPIs drugs are taken, the greater the risk of death. Considering that these drugs are widely used in the UK, these findings may cause concern. But the research has a number of important limitations: The study was conducted in a population of mostly white, older US male veterans, which might limit the abi...
Source: NHS News Feed - July 4, 2017 Category: Consumer Health News Tags: Medication Source Type: news

Your NEJM Group Today: Diabetic Foot Ulcer Clinical Pearls / Why Do We Make Bad Decisions? / New York IM Opportunities (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Resident 360: Clinical Pearls: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 26, 2017 Category: Primary Care Source Type: news

Your NEJM Group Today: Diabetic Foot Ulcer Recurrence / Capecitabine & Postsurgical Residual Breast Cancer / Colorado Cardiology Opportunity (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Review: Foot ulceration is the most common lower-extremity complication … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 19, 2017 Category: Primary Care Source Type: news

Treat type 2 diabetes 'like cancer': How THIS major complication can lead to early death
TYPE 2 diabetes should be treated like cancer - and more focus should be placed on foot ulcers which can be fatal, an expert has claimed. (Source: Daily Express - Health)
Source: Daily Express - Health - June 16, 2017 Category: Consumer Health News Source Type: news

UA surgeon: Physicians, patients must focus on remission of diabetic ulcers
(University of Arizona) Physicians and patients need to focus on remission of diabetic ulcers -- that is, extending the time between their formation, says Dr. David G. Armstrong, professor of surgery and director of the Southern Arizona Limb Salvage Alliance at the University of Arizona College of Medicine - Tucson. Armstrong says extending patients' ulcer-free days using treatment and prevention is essential, according to a report from Armstrong and his co-authors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2017 Category: International Medicine & Public Health Source Type: news

Sanuwave Health inks dev deal with eKare for wound care integration
Sanuwave Health (OTC:SNWV) said today it entered a memorandum of understanding with eKare to develop novel wound care analysis and management solutions which integrates technology from both companies. Through the deal, Sanuwave’s dermaPace wound treatment device will be linked with eKare’s inSight 3D wound imaging and analytics system to produce a comprehensive wound management solution, Suwanee, Ga.-based Sanuwave said. “We are excited to be teaming with Sanuwave to elevate inSight’s strength in imaging and analytics to develop better treatment algorithms for the dermaPace solution. This poten...
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Wound Care ekare SANUWAVE Health Inc. Source Type: news

Type 2 diabetes symptoms - THIS item of clothing could be making condition worse
TYPE 2 DIABETES is a serious health condition, and if symptoms aren't properly treated it can cause complications such as foot ulcers and even amputation. (Source: Daily Express - Health)
Source: Daily Express - Health - June 1, 2017 Category: Consumer Health News Source Type: news

Pretibial Myxedema Masquerading as a Venous Leg Ulcer Pretibial Myxedema Masquerading as a Venous Leg Ulcer
A case of non-healing leg ulcers ultimately reveals a diagnosis of pretibial myxedema. How was this difficult case diagnosed?Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 29, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Sanuwave Health taps Lithomed as Taiwanese ortho distributor
Sanuwave Health (OTC:SNWV) said today it tapped Lithomed as its orthopedic product distributor in Taiwan. Suwanee, Ga.-based Sanuwave said the selection of Lithomed was the result of an extensive search in the region, and that the contract comes with a minimum order value of $500,000. “Sanuwave has committed to deliver 3-5 new distribution partners in the second quarter and 7-10 by the end of the year. This is the first step in achieving or beating our target. We are also excited to be able to support our science advisor Dr. Chin-Jen Wang, Professor of Orthopedic Surgery at Chang Gung Memorial Hos...
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: Fink Densford Tags: Distribution Orthopedics SANUWAVE Health Inc. Source Type: news

Foot mat may help predict who will get a common diabetes complication
An experimental foot-temperature monitoring system might one day be able to detect when diabetic patients are developing foot ulcers, a common complication that can lead to infections and amputations, a small study suggests. (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
Based on new data from two large clinical trials, FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk. Patients taking canagliflozin should notify your health care professionals right away if you develop new pain or tenderness, sores or ulcers, or infections in your legs or feet. Talk to your healthcare professional if you have questions or concerns. Do not stop taking your diabete...
Source: FDA Center for Drug Evaluation and Research - What's New - May 16, 2017 Category: Drugs & Pharmacology Source Type: news

' Smart Mat' Predicts 97% of Recurrent Diabetic Foot Ulcers'Smart Mat' Predicts 97% of Recurrent Diabetic Foot Ulcers
A wireless foot-temperature-monitoring mat predicts diabetic foot ulcers with 97% accuracy in high-risk patients -- those with previously healed ulcers. False positives were an issue in the study, however.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

An External Fixator When Offloading Is Not an Option An External Fixator When Offloading Is Not an Option
This case report discusses the use of an external fixator for a diabetic plantar foot ulcer when traditional offloading techniques were not viable options.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 1, 2017 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

Human Reticular Acellular Dermal for Diabetic Foot Ulcers Human Reticular Acellular Dermal for Diabetic Foot Ulcers
A human reticular acellular dermal matrix may offer an effective alternative for diabetic foot ulcers that did not heal with the standard of care treatment.Wounds (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 24, 2017 Category: Surgery Tags: Diabetes & Endocrinology Journal Article Source Type: news

The Use of a Sea Salt-Based Spray for Diabetic Foot Ulcers The Use of a Sea Salt-Based Spray for Diabetic Foot Ulcers
A novel sea salt-based wound care spray may be a viable option in the treatment of diabetic foot ulcers.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

7 medtech stories we missed this week: April 7, 2017
[Image from unsplash.com]New studies for umbilical cord allografts and tumor targeting were published this week while another company received European CE Marking. Here are some medtech stories we missed this week but thought were still worth mentioning. 1. AMNIOX touts new umbilical cord study AMNIOX Medical announced that it has published the results of 3 studies that demonstrate the effectiveness of umbilical cord tissue for treating chronic wounds, according to an April 7 press release. The company’s cryopreserved human umbilical cord tissue, NEOX Cord 1K was tested on 29 patients who needed a wound all...
Source: Mass Device - April 7, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Clinical Trials Radiosurgery Regulatory/Compliance Research & Development Spinal Wound Care Aesculap Implant Systems Amniox AngioDynamics Cianna Medical InVivo Therapeutics MedTech Nu-Med Occlutech Source Type: news

Mayo Clinic Minute: Steps to diabetic foot care
People with diabetes face many health problems, including nerve damage and poor blood circulation. These problems make their feet vulnerable to skin sores (ulcers) that can worsen quickly and are difficult to treat.?The good news is that proper diabetes management and careful foot care can help prevent foot ulcers. The American Diabetes Association has named [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 28, 2017 Category: Databases & Libraries Source Type: news

Origin treats first patients in study of nitric oxide for diabetic foot ulcers
Origin said today that it treated the 1st patients in its dose-ranging Genesis Phase IIb-equivalent trial. The study is evaluating therapeutic quantities of plasma-generated nitric oxide as a treatment for chronic diabetic foot ulcers. The 27-week trial is slated to enroll up to 100 patients. Patients will be randomized into 1 of 4 dosing regimens, or receive standard of care as a control, to assess the safety and efficacy of plasma-generated nitric oxide, according to Origin. The company plans to treat the participants for 12 weeks and monitor them for 12 weeks following treatment. Get the full story at our sister site,&n...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Wall Street Beat Wound Care Origin Source Type: news

Audit findings back early diabetic foot ulcer intervention
A national audit has reinforced the importance of early intervention in the management of diabetic foot disease, with patients who receive expert care most quickly having the best outcomes. (Source: Nursing Times)
Source: Nursing Times - March 10, 2017 Category: Nursing Source Type: news

Report highlights need for early intervention for diabetic foot ulcers
Early intervention is important in the management of diabetic foot disease, with people who receive expert care most quickly having the best outcomes. (Source: NHS Networks)
Source: NHS Networks - March 9, 2017 Category: UK Health Source Type: news

The ideal process for launching your medical device in the UK: Interview with Michael Branagan-Harris, CEO of Device Access UK
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them! Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction of the Lap Band for obesity, endovascular graph repair, endo-laparoscopic surgery, and the DaVinci robot. Since incorporating Device Access UK in 2010, Michael ...
Source: Mass Device - March 8, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Source Type: news

Report highlights need for early intervention for diabetic foot ulcers
8 March 2017: A report published today finds that early intervention is important in the management of diabetic foot disease, with people who receive expert care most quickly having the best outcomes. (Source: The IC : Obesity)
Source: The IC : Obesity - March 8, 2017 Category: Eating Disorders and Weight Management Source Type: news

Report highlights need for early intervention for diabetic foot ulcers
8 March 2017: A report published today finds that early intervention is important in the management of diabetic foot disease, with people who receive expert care most quickly having the best outcomes. (Source: The IC : Contraception)
Source: The IC : Contraception - March 8, 2017 Category: OBGYN Source Type: news

E-Qure wins FDA nod to expand chronic wound treatment device trial
Chronic wound treatment device developer E-Qure said today it won FDA approval to expand and launch a pivotal trial of its Bio-electrical Signal Therapy Device chronic wound treatment device. The New York-based company said its Bio-electrical Signal Therapy device is designed for non-invasively treating hard-to-heal chronic wounds, including pressure ulcers, diabetic foot ulcers, venous stasis ulcers and other hard to heal ulcers. E-Qure said it won conditional approval in October 2016 to conduct the safety stage of the trial, and that the FDA approved a request to increase the number of institutions in the safet...
Source: Mass Device - February 23, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Wound Care E-Qure Source Type: news

New skin-graft system a better fix for chronic wounds
More than six million cases of chronic wounds cost $20 billion each year in the United States. Diabetic ulcers, pressure sores, surgical site wounds and traumatic injuries to high-risk patients account for most wounds that won't heal. However, data indicates that a recently developed skin-graft harvesting system aids in chronic wound recovery and reduces care costs by accelerating the healing process. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 2, 2017 Category: Science Source Type: news

New skin-graft system a better fix for chronic wounds
(University of Missouri-Columbia) According to the National Institutes of Health, more than six million cases of chronic wounds cost $20 billion each year in the United States. Diabetic ulcers, pressure sores, surgical site wounds and traumatic injuries to high-risk patients account for most wounds that won't heal. However, data from a University of Missouri School of Medicine study indicates that a recently developed skin-graft harvesting system aids in chronic wound recovery and reduces care costs by accelerating the healing process. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2017 Category: Global & Universal Source Type: news

MediWound touts Phase II study
MediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6 months from the last treatment to 3 months from wound closure. The randomized phase II trial enrolled 73 patients with a variety of chronic and hard-to-heal wounds including diabetic foot ulcers and venous leg ulcers. Patients received either EscharEx or a hydrogel placebo. Get the full story at our sister site, Drug Delivery Business News. The post MediWound touts Phase II study appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 31, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wound Care MediWound Source Type: news

MiMedx touts data from study of AmnioFix, EpiFix allograft
MiMedx (NSDQ:MDXG) today announced the publication of a study of its AmnioFix and EpiFix allografts in treating myocardial infarction patients, touting enhanced vascularization and recruitment of autologous stem cells within infarcted cardiac tissue. Data from the study was published in the Journal of Cardiology & Cardiovascular Therapy, the Marietta, Ga.-based company said. “There is a critical need for novel and innovative therapies for effective treatments following myocardial infarction and to promote regeneration of cardiac tissues. At present, total heart transplants and left ventricular assist devices...
Source: Mass Device - January 25, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Regenerative Medicine MiMedx Group Inc. Source Type: news

​Shire fined $350M in ‘largest False Claims Act’ case of its kind
The federal Justice Department said that Shire plc, a global drug company with U.S. headquarters in Lexington, will pay $350 million in what it said is “the largest False Claims Act recovery by the United States in a kickback case involving a medical device.” The settlement relates to a company Shire bought in 2011 called Advanced BioHealing, which developed a bioengineered human skin substitute for the treatment of diabetic foot ulcers called Dermagraft. Shire sold the product in 2014. In a… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 11, 2017 Category: Biotechnology Authors: Don Seiffert Source Type: news

Patients' own DNA can help kickstart repair mechanisms in the body
The gel was developed by the UK company Biotherapy Services, and worked in nine out of ten cases. According to research, 40 per cent of diabetic ulcers take at least three months to heal. (Source: the Mail online | Health)
Source: the Mail online | Health - January 2, 2017 Category: Consumer Health News Source Type: news

Protective Sensation, Neuropathy and Foot Ulceration in T2D Protective Sensation, Neuropathy and Foot Ulceration in T2D
Could certain characteristics help determine the development of these complications in type 2 diabetes?BMJ Open Diabetes Research & Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

NanoVibronix lands Health Canada nod for patch-based wound healing device
NanoVibronix (NSDQ:NVBXU) said today that it won approval from Health Canada to sell its WoundShield device in Canada. The Elmsford, N.Y.-based company has also won CE mark approval for the device in the European Union. The WoundShield system is a patch-based ultrasound device that increases local capillary perfusion and tissue oxygenation to facilitate soft tissue regeneration, according to NanoVibronix. The company’s device uses low-frequency ultrasound waves to accelerate wound healing, prevent biofilms from forming and disrupt bacteria colonization. NanoVibronix’s portfolio of devices, including WoundShield...
Source: Mass Device - December 28, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes Regenerative Medicine Regulatory/Clearance Ultrasound Wall Street Beat Wound Care NanoVibronix Inc Source Type: news

MiMedx touts Aetna reimbursement win for EpiFix implant
MiMedx (NSDQ:MDXG) said today that it won coverage from Aetna Inc. for its EpiFix allograft effective December 23rd. The insurance company classified EpiFix as “medically necessary” for the treatment of partial and full-thickness neuropathic diabetic foot ulcers when used in combination with standard diabetic ulcer care. The non-viable cellular amniotic membrane allograft helps to regenerate soft tissue by delivering extracellular matris proteins, growth factors and other proteins found in amniotic tissue, according to MiMedx. “We are very pleased to have received coverage from Aetna and with the sig...
Source: Mass Device - December 28, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes Legal News Regulatory/Clearance Wall Street Beat Wound Care MiMedx Group Inc. Source Type: news

Integra LifeSciences shareholders approve 2-for-1 reverse stock split
Integra LifeSciences (NSDQ:IART) said today that its shareholders have approved a 2-for-1 stock split, alongside an increase from 60 million to 240 million shares of stock. Shares are expected to be distributed by January 3, with the adjusted stock price expected to be reflected on the market the next day. The split, which will put a second share in the hands of every shareholder, went into effect yesterday according to an SEC filing. In January, Integra LifeSceinces said it won expanded FDA approval for its Omnigraft dermal regeneration matrix, now indicated to treat diabetic foot ulcers. The device, made of silicone, cow...
Source: Mass Device - December 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Integra LifeSciences Corp. Source Type: news

Skin cells'crawl' together to heal wounds treated with unique hydrogel layer
Scientist have demonstrated for the first time that their peptide-hydrogel biomaterial prompts skin cells to'crawl'toward one another, closing chronic, non-healing wounds often associated with diabetes, such as bed sores and foot ulcers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 14, 2016 Category: Science Source Type: news

Skin cells 'crawl' together to heal wounds treated with unique hydrogel layer
(University of Toronto Faculty of Applied Science& Engineering) A team led by Professor Milica Radisic in U of T Engineering has demonstrated for the first time that their peptide-hydrogel biomaterial prompts skin cells to 'crawl' toward one another, closing chronic, non-healing wounds often associated with diabetes, such as bed sores and foot ulcers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 14, 2016 Category: Global & Universal Source Type: news

BRH Medical Receives Patents in Both the USA and in China for Its Innovative Wound Healing Therapy
JERUSALEM, Nov. 8, 2016 -- (Healthcare Sales & Marketing Network) -- BRH Medical announced today that the USA and China issued patents for its innovative wound healing system for the treatment of Diabetic Leg Wounds, Venous Leg Ulcers, and Pressure Ulcers... Devices, Wound Care BRH Medical (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2016 Category: Pharmaceuticals Source Type: news